When was SynapDx founded?

SynapDx was founded in 2010 and raised its 1st funding round within a year of its incorporation.

Where is SynapDx located?

SynapDx is headquartered in Southborough, United States.

Is SynapDx a funded company?

SynapDx is a funded company, having raised a total of $32.7M across 5 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jun 02, 2010.

When was the latest funding round of SynapDx?

SynapDx's latest funding was a $***** Series C round on Jul 24, 2013, with participation from 5 investors.

Where does SynapDx rank among its competitors?

SynapDx ranks 4th amongst 10 active competitors, of which 4 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was MARAbio, which secured $19.1M in Sep, 2024.

Who are the top competitors of SynapDx?

SynapDx's top competitors include Linus Biotechnology, MARAbio and Lineagen. Among them, MARAbio secured the most recent funding round in September, 2024.

SynapDx - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of blood-based diagnostic tests for the early detection of autism. It uses RNA-sequencing to evaluate gene expression levels for specific autism-related markers. The company collaborates with ASD experts at leading institutions. SynapDx’s investors include Google Ventures, North Bridge Venture Partners, General Catalyst Partners, LabCorp, Windham Venture Partners, Casdin Capital, Foundation Medical Partners, and The Kraft Group.

Website: synapdx.com
Social

Key Metrics

Founded Year

2010

Location

Southborough, United States

Stage

Deadpooled

Total Funding

$32.7M in 5 rounds

Latest Funding Round

Series C, Jul 24, 2013, $*****

Investors

Bain Capital Ventures & 8 more

Ranked

4^th among 10 active competitors

Similar Companies

Linus Biotechnology & 11 more

View SynapDx's full profile

SynapDx has raised a total funding of $32.7M over 5 rounds. Its first funding round was on Jun 02, 2010. Its latest funding round was a Series C round on Jul 24, 2013 for $*****. 5 investors participated in its latest round. SynapDx has 9 institutional investors.

Here is the list of recent funding rounds of SynapDx:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 24, 2013	9939289	Series C	9887745	9277948	7366226	4895980
Mar 27, 2013	7757741	Series C	9424568	9480288	7854247	The Kraft Group
Feb 21, 2013	2413065	Series C	5317889	9129582	2658866	LabCorp

Access funding benchmarks and valuations. Sign up today!

View details of SynapDx's funding rounds and investors

The founders of SynapDx are Stanley Lapidus and Jeffery Luber.

Here are the details of SynapDx's key team members:

Stanley Lapidus: President, CEO & Founder of SynapDx and founder of 2 other companies, Pillar VC and Helicos BioSciences. They serve on the boards of 2 companies.
Jeffery Luber: Co-founder, Vice President Corporate Development of SynapDx.

View details of SynapDx's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of SynapDx include Linus Biotechnology, MARAbio and Lineagen. Here is the list of Top 10 competitors of SynapDx, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Linus Biotechnology 2020, New York City (United States), Series A	Developer of diagnostic tests for central nervous system and gastrointestinal disorders	$47.6M	GreatPoint Ventures, Bow Capital & 3 others	55/100
2nd	MARAbio 2016, Salt Lake City (United States), Series A	Developer of blood test for detecting maternal autoantibody-related autism	$19.1M	MAK Capital, Moai Capital	48/100
3rd	Lineagen 2002, Salt Lake City (United States), Acquired	Sequencing-based diagnostic test and consultative services for autism	$66.9M	Health Quest Capital, Signal Peak & 10 others	44/100
4th	SynapDx 2010, Southborough (United States), Deadpooled	Developer of blood-based diagnostic tests for the early detection of autism	$32.7M	Flare Capital Partners, The Kraft Group & 7 others	38/100
5th	SensOmics 2007, Toronto (Canada), Seed	Provider of precision medicine for children's health	-	iSeed Ventures, Asset Management Ventures	26/100
6th	FBB Biomed 2020, Coralville (United States), Seed	Developer of in-vitro diagnostic test for COVID-19 and neurological diseases	$401K	-	25/100
7th	Leeza 2023, Hyderabad (India), Unfunded	AI-powered screening assessments for the early detection of autism	-	-	24/100
8th	Pediatric Bioscience 2006, Sacramento (United States), Deadpooled	Blood biomarker based diagnostics for Autism Spectrum Disorders	$2.44M	Tech Coast Angels, Arizona Tech Investors	24/100
9th	Analutos 2010, Sunderland (United Kingdom), Unfunded	Mass Spectrometry-based tests for autism spectrum disorders & Dysbiosis	-	-	23/100
10th	Autism Biotech 2011, Belfast (United Kingdom), Deadpooled	Biochemical test for the early diagnosis of autism	$51.3K	Co-Fund NI, Schneider Investment Associates ... & 3 others	21/100